日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Targeted Degradation of eEF2K by a Structure-Guided PROTAC Strategy for the Treatment of Triple-Negative Breast Cancer.

通过结构导向的 PROTAC 策略靶向降解 eEF2K 治疗三阴性乳腺癌。

Cao Shijun, Zhong Changxin, Jiang Shilong, Li Yungui, Xi Yang, Xiao Mingxuan, Jiang Ting, Wan Xiaoya, Chen Zonglin, Yu Xiaohui, Cheng Yan

GPX4-AUTAC induces ferroptosis in breast cancer by promoting the selective autophagic degradation of GPX4 mediated by TRAF6-p62.

GPX4-AUTAC 通过促进 TRAF6-p62 介导的 GPX4 选择性自噬降解,诱导乳腺癌细胞发生铁死亡。

Gong Rong, Wan Xiaoya, Jiang Shilong, Guan Yidi, Li Yizhi, Jiang Ting, Chen Zonglin, Zhong Changxin, He Linhao, Xiang Zhongyuan, Yang Junya, Xu Biao, Yang Jinming, Cheng Yan

Serine/Threonine Kinase 33 as a Novel Target of Bufalin in Treatment of Triple-Negative Breast Cancer.

丝氨酸/苏氨酸激酶 33 是布法林治疗三阴性乳腺癌的新靶点。

Jiang Shilong, Liu Junyan, Li Hui, Zou Chan, Wan Xiaoya, Gong Rong, Jiang Ting, Zhong Changxin, Chen Zonglin, Zhu Zewu, Cao Dongsheng, Cheng Yan

Identification of a Novel Substrate for eEF2K and the AURKA-SOX8 as the Related Pathway in TNBC.

在三阴性乳腺癌中鉴定出 eEF2K 的新底物和 AURKA-SOX8 的相关通路

Wan Xiaoya, Gong Rong, Zhao Xiaobao, Li Yizhi, Shan Tianjiao, Zhong Changxin, Zhu Rongfeng, Chen Zonglin, Jiang Shilong, He Linhao, Cao Shijun, Tian Sheng, Yang Jinming, Ye Na, Yi Wenjun, Cheng Yan

Discovery of LD-110 as an Effective LSD1 PROTAC Degrader for the Treatment of Esophagus Squamous Cancer.

发现 LD-110 是一种有效的 LSD1 PROTAC 降解剂,可用于治疗食管鳞状细胞癌。

Zhuo Jiezhen, Zhai Danyi, Liu Lihua, Yin Yudong, Zhong Changxin, Chen Qian, You Xiahong, Chen Liangzhen, Yu Qing, Xiong Xiufang, Sun Yi, Han Xin

Neddylation inhibitor MLN4924 enhances H3K18 lactylation via binding to LDH and downregulates ITGB4 to block metastasis.

Neddylation抑制剂MLN4924通过与LDH结合增强H3K18乳酸化,并下调ITGB4以阻止转移。

Yu Hongfei, Zhou Qiyin, Chen Yongxia, Zhong Changxin, Fu Tingting, Xiong Xiufang, Zhu Feng, Wang Linbo, Sun Yi